SG Americas Securities LLC Has $688,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 274.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,497 shares of the medical research company’s stock after purchasing an additional 2,564 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $688,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Ronald Blue Trust Inc. acquired a new position in Charles River Laboratories International in the second quarter valued at $25,000. Trust Co. of Vermont acquired a new position in Charles River Laboratories International in the second quarter valued at $29,000. SRS Capital Advisors Inc. acquired a new position in Charles River Laboratories International in the second quarter valued at $35,000. Covestor Ltd lifted its holdings in Charles River Laboratories International by 100.0% in the first quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after buying an additional 87 shares during the period. Finally, Salem Investment Counselors Inc. lifted its holdings in Charles River Laboratories International by 65.5% in the second quarter. Salem Investment Counselors Inc. now owns 240 shares of the medical research company’s stock valued at $51,000 after buying an additional 95 shares during the period. Institutional investors and hedge funds own 97.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CRL. Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $275.00 to $285.00 and gave the company an “outperform” rating in a report on Wednesday, January 11th. William Blair reiterated an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, November 2nd. Credit Suisse Group dropped their price objective on shares of Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. Finally, Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $250.00 to $241.00 and set an “equal weight” rating on the stock in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $297.38.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 6,409 shares of the stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $224.25, for a total value of $1,437,218.25. Following the completion of the sale, the executive vice president now owns 20,232 shares in the company, valued at approximately $4,537,026. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Joseph W. Laplume sold 534 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $216.36, for a total transaction of $115,536.24. Following the completion of the transaction, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at approximately $4,377,395.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 6,409 shares of the stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the transaction, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at $4,537,026. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,077 shares of company stock worth $2,334,821. Insiders own 1.10% of the company’s stock.

Charles River Laboratories International Trading Up 4.1 %

NYSE:CRL opened at $243.17 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40. The firm has a market cap of $12.37 billion, a price-to-earnings ratio of 28.64, a price-to-earnings-growth ratio of 1.46 and a beta of 1.29. Charles River Laboratories International, Inc. has a 52 week low of $181.36 and a 52 week high of $349.84. The firm has a 50-day moving average price of $226.53 and a two-hundred day moving average price of $218.49.

Charles River Laboratories International (NYSE:CRLGet Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The medical research company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.51 by $0.12. The firm had revenue of $989.16 million during the quarter, compared to analyst estimates of $978.65 million. Charles River Laboratories International had a net margin of 11.54% and a return on equity of 20.93%. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.89 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.